一、临床药理学与治疗学 (2024年第115卷第2期)

February 2024 - Volume 115 - Issue 2 (2024年2月第115卷第2期)
https://ascpt.onlinelibrary.wiley.com/toc/15326535/2024/115/2

Editorial（社论）
1. 中国临床药理学进展：以随机对照研究推进基因型指导的精准医学
(Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype-Guided Precision Medicine)
作者：Liang Zhao* (Division of Quantitative Methods in Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, FDA, USA)

Perspective（视角）
1. CYP2C：TG单倍型目前的临床影响是什么？
(What is the Current Clinical Impact of the CYP2C: TG Haplotype?)
作者：Magnus Ingelman-Sundberg* (Section of Pharmacogenetics, Department of Physiology and Pharmacology, Biomedicum 5B, Karolinska Institutet, Sweden)
2. 对 “CYP2C：TG单倍型目前的临床影响是什么？” 的回复
(Response to “What is the Current Clinical Impact of the CYP2C: TG Haplotype?”)
作者：Pablo Zubiaur* (Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Spain)
3. 为每一位癌症患儿开发治疗方法—2023年ASCPT会议科学会议总结
(Developing Therapy for Every Kid With Cancer – Summary of a Scientific Session at the 2023 ASCPT Meeting)
作者：Jason N. Moore, Clinton F. Stewart* (Office of Clinical Pharmacology, Center for Drug Evaluation and Research, FDA, USA; Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, USA)

White Paper（白皮书）
1. IQ联盟对CAR-T和TCR-T细胞疗法发展的生物分析和免疫原性评估方面的最佳实践的看法
(An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR-T and TCR-T Cellular Therapies Development)
作者：Jochem Gokemeijer* (Discovery Biotherapeutics, Bristol Myers Squibb, USA)

Reviews（综述）
1. 创建定量系统药理学指导的罕见病药物开发路线图：一份研讨会报告
(Creating a Roadmap to Quantitative Systems Pharmacology–Informed Rare Disease Drug Development: A Workshop Report)
作者：Jane P.F. Bai* (Office of Clinical Pharmacology, Center for Drug Evaluation and Research, FDA, USA)
2. 萘莫司他可降低ERCP术后胰腺炎的发生率：一项随机对照试验的系统综述和Meta分析
(Nafamostat Reduces the Incidence of post-ERCP Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials)
作者：István László Horváth, Dezső Csupor* (Centre for Translational Medicine, Semmelweis University, Hungary)

Research（研究）
1. 6-巯基嘌呤在中国ALL（急性淋巴细胞白血病）患儿中的个体化应用：一项多中心随机对照试验
(Individualized Use of 6-Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial)
作者：Yue Zhou, Xiu-Li Ju* (Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, China; Department of Pediatrics, Qilu Hospital of Shandong University, China)
2. 健康成人空肠和肝脏主要和次要药物代谢酶的基因表达和蛋白丰度的比较研究
(Comparative Intra-Subject Analysis of Gene Expression and Protein Abundance of Major and Minor Drug Metabolizing Enzymes in Healthy Human Jejunum and Liver)
作者：Christoph Wenzel, Stefan Oswald* (Department of Pharmacology, University Medicine Greifswald, Germany; Institute of Pharmacology and Toxicology, Rostock University Medical Center, Germany)
3. 维生素D口服替代治疗儿童肥胖相关哮喘：VDORA1随机临床试验
(Vitamin D Oral Replacement in Children With Obesity Related Asthma: VDORA1 Randomized Clinical Trial)
作者：Brian O'Sullivan, Jessica Snowden* (Geisel School of Medicine at Dartmouth, USA; University of Arkansas for Medical Sciences, USA)
4. 应用模型引导的万古霉素剂量优化以解决危重先天性心脏病婴幼患儿的肾脏成熟延迟问题
(Model-Informed Vancomycin Dosing Optimization to Address Delayed Renal Maturation in Infants and Young Children with Critical Congenital Heart Disease)
作者：Yuko Shimamoto, Masahiro Okuda* (Department of Pharmacy, National Cerebral and Cardiovascular Center, Japan; Department of Hospital Pharmacy, Graduate School of Medicine, Osaka University, Japan)
5. ANTHRASIL治疗健康成人、肥胖成人和儿童吸入性炭疽的动物-人体剂量转化
(Animal-to-Human Dose Translation of ANTHRASIL for Treatment of Inhalational Anthrax in Healthy Adults, Obese Adults, and Pediatric Subjects)
作者：Martin Beliveau, Srinivas Kammanadiminti* (Integrated Drug Development, Canada; Emergent BioSolutions Inc., Canada)
6. 戈沙妥珠单抗的上市后安全性：基于FDA不良事件报告系统的药物警戒研究
(Postmarketing Safety of Sacituzumab Govitecan: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System)
作者：Xingxing Li, Wei Mao* (Department of Pharmacy, The First Affiliated Hospital of Army Medical University (Third Military Medical University), China; Department of Pharmacy, Nan'an People's Hospital of Chongqing, China)
7. 以卡培他滨为基础的抗癌方案治疗的DPYD野生型患者的严重毒性预测诺模图
(A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens)
作者：Jonathan E. Knikman* (Division of Pharmacology, The Netherlands Cancer Institute, The Netherlands)
8. 基于体外-体内外推法预测Tusamitamab Ravtansine（一种DM4结合物）给药后出现的CYP下调
(Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4-Conjugate), Based on an In Vitro–In Vivo Extrapolation Approach)
作者：Clemence Pouzin* (Sanofi R&D, Pharmacokinetics Dynamics and Metabolism Department, France)
9. 缓解瘙痒和患者报告耐受性的人群剂量-反应时间分析支持Linerixibat的III期剂量选择
(Population Dose–Response-Time Analysis of Itch Reduction and Patient-Reported Tolerability Supports Phase III Dose Selection for Linerixibat)
作者：Fernando Carreño, Brandon Swift* (UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, USA; GSK, Durham, USA)
10. 建立用于全面预测Tucatinib CYP2C8相互作用的新型敏感探针底物和中度抑制剂模型
(Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib)
作者：Ian E. Templeton, Anthony J. Lee* (Certara, UK Ltd. (Simcyp Division), UK; Quantitative Pharmacology and Disposition, Seagen Inc., USA)
11. 茄啶作为膳食来源的CYP2D6活性标记物在体内的营养验证
(Nutrimetric Validation of Solanidine as Dietary-Derived CYP2D6 Activity Marker In Vivo)
作者：Julian Peter Müller* (Institute of Clinical Pharmacology, University Hospital of RWTH Aachen, Germany)
12. 哺乳期流感患者中奥司他韦药代动力学观察研究
(An Observational Study on the Pharmacokinetics of Oseltamivir in Lactating Influenza Patients)
作者：Eszter Fodor, Péter Ferdinandy* (Pharmahungary Group, Hungary)
13. 指导维拉帕米作为结核病辅助治疗的剂量探索研究
(A Dose-Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis)
作者：Chandrasekaran Padmapriyadarsini* (National Institute for Research in Tuberculosis, India)
14. 通过OS（总生存期）预后评分匹配构建肺癌临床试验的外部对照
(Matching by OS Prognostic Score to Construct External Controls in Lung Cancer Clinical Trials)
作者：Hugo Loureiro, Anna Bauer-Mehren* (Data and Analytics, Pharma Research and Early Development, Roche Innovation Center Munich (RICM), Germany)
15. 首创新药的起源：创新与临床效益
(The Origin of First-in-Class Drugs: Innovation Versus Clinical Benefit)
作者：Leeza Osipenko* (Department of Health Policy, LSE, UK)
16. 纵向循环肿瘤DNA模型用于预测一线突变型表皮生长因子受体非小细胞肺癌的疾病进展
(Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer)
作者：Martin Johnson* (Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, UK)
17. BST2高表达促进IFN-α的抗HBV作用，BST2基因变异预测HBeAg阳性慢性乙型肝炎患者的PegIFNα治疗应答
(Higher BST2 Expression Promotes the Anti-HBV Effect of IFN-α and BST2 Genetic Variant Predicts PegIFNα Treatment Response of HBeAg-Positive Chronic Hepatitis B Patients)
作者：Jiaxuan Chen, Jinlin Hou* (State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, China)

二、药理学评论

（本刊为双月刊，每两月更新一次，详见2024年3月更新）

三、先进药物输送评论 (2024年第205卷)

February 2024 - Volume 205 (2024年2月第205卷)
https://www.sciencedirect.com/journal/advanced-drug-delivery-reviews/vol/205/suppl/C

Review article（综述文章）
1. 纳米医学/药物介导的声催化疗法
(Nanomedicine/materdicine-enabled sonocatalytic therapy)
作者：Meiqi Chang, Yang Dong* (Laboratory Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, China; Department of Breast Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, China)
2. 转移细胞疗法用于治疗自身免疫性疾病
(Translation of cell therapies to treat autoimmune disorders)
作者：Jinal M. Mehta, Jessica D. Weaver* (School of Biological and Health Systems Engineering, Arizona State University, USA)
3. 化妆品输送系统将科学从实验室转化为市场的障碍：一个工业视角
(Hurdles in translating science from lab to market in delivery systems for Cosmetics: An industrial perspective)
作者：Sheila Siqueira Andrade, João Paulo Figueiró Longo* (PlateInnove Biotechnology, Brazil; Department of Science and Innovation, Glia Innovation, Brazil)
4. 用于疾病成像和体内治疗的超声激活探针
(Ultrasound activated probe for disease imaging and therapy In-Vivo)
作者：Xing Liu, Ying Wu* (Department of Radiology and Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, China; College of Chemistry, Beijing University of Chemical Technology, China)
5. 前言：RNA治疗的新时代
(Preface: A new era of RNA-based therapies)
作者：Sun Hwa Kim*, Kanjiro Miyata* (Medicinal Materials Research Center, Biomedical Research Institute at Korea Institute of Science and Technology (KIST), Korea)
6. 长效疗法：发展策略和临床意义
(Long-acting therapeutics: Development strategies and clinical significance)
作者：Sanyog Jain*, Anil B. Jindal* (Centre for Pharmaceutical Nanotechnology, Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), India)
7. 甲真菌病治疗的新发现和临床进展：一种机制的洞察
(Novel Discoveries and Clinical Advancements for Treating Onychomycosis: A Mechanistic Insight)
作者：Jitesh Kumar Behera, Ashay Jain* (Adarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit University, Saharanpur, India; Formulation Research & Development-Non-Orals Sun Pharmaceutical Industries Ltd, India)
8. “未来方向”—药物开发和递送以及再生医学领域的新突破性进展
(“Future Directions” – Novel breakthrough developments in the fields of drug development & delivery, and regenerative medicine)
作者：Katja Schenke-Layland* (Institute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, Eberhard Karls University Tübingen, Germany)
9. 超声机器人用于精准治疗
(Ultrasound robotics for precision therapy)
作者：Alexia Del Campo Fonseca, Daniel Ahmed* (Department of Mechanical and Process Engineering, Acoustic Robotics Systems Lab, ETH Zurich, Switzerland)
10. 发挥超声作用：超声大脑干预的光学和光声监测
(Shedding light on ultrasound in action: Optical and optoacoustic monitoring of ultrasound brain interventions)
作者：Maria Eleni Karakatsani, Xosé Luís Deán-Ben* (Institute for Biomedical Engineering and Institute of Pharmacology and Toxicology, Faculty of Medicine, University of Zurich, Switzerland)
11. 超声-纳米囊泡在诊疗中的相互作用
(Ultrasound-nanovesicles interplay for theranostics)
作者：Jingyi Liu, Qing You, Ling Zhu* (CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, China)
12. mRNA脂质纳米粒的免疫刺激特性
(The immunostimulatory nature of mRNA lipid nanoparticles)
作者：Preeti Sharma, Dan Peer* (Laboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel)

四、药理学发展趋势 (2024年第45卷第2期)

Feburary 2024 - Volume 45 - Issue 2 (2024年2月第45卷第2期)
https://www.cell.com/trends/pharmacological-sciences/issue?pii=S0165-6147(23)X0003-0

Forum（论坛）
1. 利用深度学习增强配体对接
(Harnessing deep learning for enhanced ligand docking)
作者：Xujun Zhang, Chang-Yu Hsieh* (College of Pharmaceutical Sciences, Zhejiang University, China)

Opinion（意见）
1. 裸盖菇素的治疗效果是否涉及肠道作用?
(Do the therapeutic effects of psilocybin involve actions in the gut?)
作者：Felicia Reed, Claire J. Foldi* (Department of Physiology, Monash University, Australia)
2. 类风湿关节炎中的代谢物感应GPCRs
(Metabolite-sensing GPCRs in rheumatoid arthritis)
作者：Xuezhi Yang, Yingjie Zhao* (Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Ministry of Education, China; Department of Clinical Pharmacology, The Second Affiliated Hospital of Anhui Medical University, China)
3. 利用空间组学发展精准肉瘤治疗
(Leveraging spatial omics for the development of precision sarcoma treatments)
作者：Cui Tu, Fernando Souza-Fonseca-Guimaraes* (Frazer Institute, Faculty of Medicine, The University of Queensland, Australia)

Feature Reviews（专题综述）
1. 肿瘤铁稳态与免疫调节
(Tumor iron homeostasis and immune regulation)
作者：Yan-Yu Zhang, Rui-Hua Xu* (Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University, China)
2. 关于衰老机制和干预的新兴表观遗传学见解
(Emerging epigenetic insights into aging mechanisms and interventions)
作者：Zeming Wu, Weiqi Zhang* (State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, China; Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, China)

Reviews（综述）
1. SIRT3在癌症中的环境依赖性作用
(Context-dependent role of SIRT3 in cancer)
作者：Jin Zhang, Bo Han* (Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, China; State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, College of Medical Technology and School of Pharmacy, Chengdu University of Traditional Chinese Medicine, China)

五、药理学与治疗学 (2024年第254卷)

February 2024 - Volume 254 (2024年2月第254卷)
https://www.sciencedirect.com/journal/pharmacology-and-therapeutics/vol/254/suppl/C

Review article（综述文章）
1. 最近的药物设计策略和有前景的抗癌靶点的关键杂环支架的鉴定
(Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets)
作者：Alia Mushtaq, Muhammad Moazzam Naseer* (Department of Chemistry, Quaid-i-Azam University, Pakistan)
2. CDNF和内质网应激：药理学和治疗可能性
(CDNF and ER stress: Pharmacology and therapeutic possibilities)
作者：Helike Lõhelaid, Mikko Airavaara* (Drug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Finland)
3. 肾脏疾病的新治疗靶点：从饥饿反应中吸取的教训
(A novel therapeutic target for kidney diseases: Lessons learned from starvation response)
作者：Kosuke Yamahara, Shinji Kume* (Department of Medicine, Shiga University of Medical Science, Japan)
4. 预测食管癌新辅助治疗反应的生物标志物发现的多组学方法：一种多维视角
(Multi-omics approaches for biomarker discovery in predicting the response of esophageal cancer to neoadjuvant therapy: A multidimensional perspective)
作者：Zhi Yang, Lina Zhao* (Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, China)
5. 小檗碱通过调节代谢紊乱预防NAFLD（非酒精性脂肪性肝病）和HCC（肝细胞癌）
(Berberine prevents NAFLD and HCC by modulating metabolic disorders)
作者：Xinyue Lin, Junmin Zhang* (School of Pharmacy, State Key Laboratory of Applied Organic Chemistry, and College of Chemistry and Chemical Engineering, Lanzhou University, China)
6. 油橄榄衍生的环烯醚萜类化合物：有益的健康作用和潜在的治疗方法
(Olea europaea L-derived secoiridoids: Beneficial health effects and potential therapeutic approaches)
作者：Simone Filardo, Rosa Sessa* (Department of Public Health and Infectious Diseases, Sapienza University, Italy)
7. 转化或替代—激素疗法对心血管风险的影响
(Transformation or replacement - Effects of hormone therapy on cardiovascular risk)
作者：Julia Kielb* (Department of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty of the Heinrich Heine University Düsseldorf, Germany)

六、药理学研究 (2024年第200卷)

February 2024 - Volume 200 (2024年2月第200卷)
https://www.sciencedirect.com/journal/pharmacological-research/vol/200/suppl/C

Review Articles（综述文章）
1. 天然产物作为线粒体功能障碍的药物调节剂，用于糖尿病及其并发症的治疗：2010年以来的更新内容
(Natural products as pharmacological modulators of mitochondrial dysfunctions for the treatment of diabetes and its complications: An update since 2010)
作者：Qian-Ru Lin, Xu-Han Liu* (Department of Neuroendocrine Pharmacology, School of Pharmacy, China Medical University, China; Department of Endocrinology, Dalian Municipal Central Hospital, China)
2. KRASG12C突变实体瘤患者接受KRASG12C抑制剂治疗后的结局：一项系统综述和Meta分析
(Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis)
作者：Qi-An Chen, Yi-Bo Gao* (Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China)
3. 循环细胞因子与高血压发病风险：一项系统综述和Meta分析
(Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis)
作者：Elisabetta Caiazzo, Pasquale Maffia* (School of Infection & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK)
4. 辅助蛋白和伴侣调节神经元烟碱受体亚型的表达和功能
(Auxiliary protein and chaperone regulation of neuronal nicotinic receptor subtype expression and function)
作者：Cecilia Gotti* (CNR, Institute of Neuroscience, Italy)
5. FDA批准的小分子蛋白激酶抑制剂的性质：2024年更新
(Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update)
作者：Robert Roskoski Jr.* (Blue Ridge Institute for Medical Research, USA)
6. IUPHAR综述：引导临床前模型在疼痛研究中的作用
(IUPHAR review: Navigating the role of preclinical models in pain research)
作者：Seyed Asaad Karimi, Loren J. Martin* (Department of Psychology, University of Toronto Mississauga, Canada)
7. 求同存异：IL-18和IL-37之间的矛盾揭示了它们在癌症中的共同靶点
(Agree to disagree: The contradiction between IL-18 and IL-37 reveals shared targets in cancer)
作者：Dongjie Wang, Bitian Zhang, Chun-Kwok Wong* (Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, China)
8. CLDN5：从结构和调节到在肿瘤和中枢神经系统疾病以外的其他疾病中的作用
(CLDN5: From structure and regulation to roles in tumors and other diseases beyond CNS disorders)
作者：Yao Ling, Xinxin Kang, Ying Yi, Huinan Qu* (Department of Histology and Embryology, College of Basic Medical Sciences, Jilin University, China)
9. 通过药用植物的活性代谢物缓解坐骨神经痛损伤诱导的神经病理性疼痛
(Mitigation of sciatica injury-induced neuropathic pain through active metabolites derived from medicinal plants)
作者：Abdul Nasir, Haroon Khan* (Department of Anesthesiology, Second Affiliated Hospital of Zhengzhou University, China; Department of Pharmacy, Abdul Wali Khan University Mardan, Pakistan)
10. 黄蜂毒液中抗菌肽的结构和功能特征
(Unwrapping the structural and functional features of antimicrobial peptides from wasp venoms)
作者：Harry Morales Duque* (Centro de Análises Proteômicas e Bioquímicas, Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brazil)
11. 对核酸传感器AIM2的新见解：癌症靶向治疗的潜在益处
(New insights into nucleic acid sensor AIM2: The potential benefit in targeted therapy for cancer)
作者：Jian-Zhou Cui*, Lina H.K. Lim* (Translational Immunology Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore)
12. 氯胺酮抗抑郁作用中mGluR5调节的分子视角
(A molecular perspective on mGluR5 regulation in the antidepressant effect of ketamine)
作者：Ola Sobhy A. Elmeseiny, Heidi Kaastrup Müller* (Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Denmark)

Research article（研究文章）
1. 清达颗粒与缬沙坦胶囊治疗中国1级低中危高血压患者的有效性和安全性：一项随机、双盲、双模拟、非劣效性、多中心试验
(Efficacy and safety of Qingda granule versus valsartan capsule in Chinese grade 1 hypertensive patients with low-moderate risk: A randomized, double-blind, double dummy, non-inferiority, multi-center trial)
作者：Hua Qu, Chang-geng Fu* (Xiyuan Hospital, China Academy of Chinese Medical Sciences, China)
2. 欧洲DILI研究路线图。来自成本行动ProEuroDILINet的提议
(Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet)
作者：M.I. Lucena* (Servicios de Aparato Digestivo y Farmacología Clínica, Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Universidad de Málaga, Spain)
3. NSD2通过甲基化STAT1调控drp1介导的线粒体分裂在慢性移植肾间质纤维化中的作用
(NSD2 modulates Drp1-mediated mitochondrial fission in chronic renal allograft interstitial fibrosis by methylating STAT1)
作者：Jianjian Zhang, Ruoyun Tan* (Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, China)
4. 药用植物源性细胞外囊泡的生物活性化合物和生物学功能
(Bioactive compounds and biological functions of medicinal plant-derived extracellular vesicles)
作者：Siyu Hao, Yuan Yuan* (National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, China)
5. 针对代谢紊乱中的系统性炎症。是预防心血管疾病的候选治疗药物？
(Targeting systemic inflammation in metabolic disorders. A therapeutic candidate for the prevention of cardiovascular diseases?)
作者：Elena Domingo, Patrice Marques, Laura Piqueras*, Maria-Jesus Sanz* (Institute of Health Research INCLIVA, University Clinic Hospital of Valencia, Spain)
6. 遗传药理学、药物基因组学和个体化医学的发展
(Developments in pharmacogenetics, pharmacogenomics, and personalized medicine)
作者：Francisco Abad-Santos* (Clinical Pharmacology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid (UAM), CIBEREHD, Instituto de Investigación Sanitaria La Princesa (IP), Spain)
7. 尼可地尔减轻糖尿病心肌病心肌微血管铁死亡：线粒体定位AMPK-Parkin-ACSL4信号通路的作用
(Nicorandil alleviates cardiac microvascular ferroptosis in diabetic cardiomyopathy: Role of the mitochondria-localized AMPK-Parkin-ACSL4 signaling pathway)
作者：Zhangwei Chen, Chenguang Li* (Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, China)
8. 富含peu- MIR2916 -p3的大蒜外泌体通过重塑肠道菌群，尤其是通过增强抗结肠炎拟杆菌thetaiotaomicron来改善小鼠结肠炎
(peu-MIR2916-p3-enriched garlic exosomes ameliorate murine colitis by reshaping gut microbiota, especially by boosting the anti-colitic Bacteroides thetaiotaomicron)
作者：Xiaoyuan Wang, Ting Li* (Shaanxi Engineering Laboratory for Food Green Processing and Safety Control, and Shaanxi Key Laboratory for Hazard Factors Assessment in Processing and Storage of Agricultural Products, College of Food Engineering and Nutritional Science, Shaanxi Normal University, China)
9. 靶向CD38/ADP -核糖基环化酶作为一种新型治疗策略来鉴定三种有效的白细胞减少症激动剂
(Targeting CD38/ ADP-ribosyl cyclase as a novel therapeutic strategy for identification of three potent agonists for leukopenia treatment)
作者：Yuanzhi Liu, Songyot Anuchapreeda* (Division of Clinical Microscopy, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand)
10. mmp14高表达巨噬细胞协调进行性肺纤维化SR-Ag诱导的超敏性肺炎
(MMP14^high macrophages orchestrate progressive pulmonary fibrosis in SR-Ag-induced hypersensitivity pneumonitis)
作者：Dan Peng, Elaine Lai-Han Leung* (Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University Medical School, China; Cancer Center, Faculty of Health Sciences, University of Macau, China)
11. 将被批准用于免疫介导的炎症性疾病的17种生物制剂的临床试验人群代表性与真实世界用户进行比较：对意大利VALORE项目中66,639种生物制剂用户的外部效度分析
(Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project)
作者：Ylenia Ingrasciotta, Gianluca Trifirò* (University of Verona, Department of Diagnostics and Public Health, Italy)
12. IUPHAR综述：治疗物质使用障碍的药物新策略
(IUPHAR Review: New strategies for medications to treat substance use disorders)
作者：Ivan D. Montoya* (Division of Therapeutics and Medical Consequences, National Institute on Drug Abuse, USA)
13. 鉴定法舒地尔为合作药物，通过抑制GLI2介导的hedgehog信号通路促进乐伐替尼在肝细胞癌中的抗肿瘤作用
(Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway)
作者：Yilan Huang, Aiwu Ke* (Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion Ministry of Education, China)
14. 药物性心房颤动。一份被遗忘的不良反应的叙述性综述
(Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect)
作者：Juan Tamargo, Ricardo Caballero* (Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón, Spain)
15. 小剂量奥拉帕尼通过加速线粒体自噬流减少铁死亡，从而改善脓毒症心功能
(Low-dose Olaparib improves septic cardiac function by reducing ferroptosis via accelerated mitophagy flux)
作者：Ruixue Liu, Gautam Sethi* (Department of Anesthesiology, The Second Affiliated Hospital of Chongqing Medical University, China)

七、抗病毒研究 (2024年第222卷)

February 2024 - Volume 222 (2024年2月第222卷)
https://www.sciencedirect.com/journal/antiviral-research/vol/222/suppl/C

Research article（研究文章）
1. PZR通过抑制RIG-I和MDA5介导的干扰素信号通路中的MAVS活化来抑制对RNA病毒感染的固有免疫反应
(PZR suppresses innate immune response to RNA viral infection by inhibiting MAVS activation in interferon signaling mediated by RIG-I and MDA5)
作者：Rilin Deng, Lini Zhang, Haizhen Zhu* (Institute of Pathogen Biology and Immunology, College of Biology, State Key Laboratory of Chemo/Biosensing and Chemometrics, Hunan University, China)
2. 猫感染性腹膜炎病毒ORF7a是一种参与猫炎症病理的致病因子
(Feline infectious peritonitis virus ORF7a is a virulence factor involved in inflammatory pathology in cats)
作者：Zhe Jiao, Yuejun Shi*, Guiqing Peng* (National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, China)
3. 暴露于丙型肝炎病毒后，血清转化的缺失与KIR-HLA基因型组合无关（GEHEP-012研究）
(The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations (GEHEP-012 study))
作者：Carmen Martín-Sierra, Luis Miguel Real* (Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Spain)
4. 更昔洛韦和马立巴韦交叉耐药性再探讨：典型巨细胞病毒突变体的相对药物敏感性
(Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants)
作者：Sunwen Chou* (Department of Veterans Affairs Medical Center, USA)
5. 一个灵活的、基于图像的、高通量平台，包括深入的细胞分析，以识别脱靶效应有限的广谱冠状病毒抗病毒药物
(A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects)
作者：Jordi Doijen, Ellen Van Damme* (Global Public Health R&D, Janssen Pharmaceutica NV, Belgium)
6. TXM肽可抑制SARS-CoV-2感染、合胞体形成，并降低炎症后果
(TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences)
作者：Tea Govednik, Daphne Atlas* (Department of Synthetic Biology and Immunology, National Institute of Chemistry, Slovenia; Hebrew University of Jerusalem, Israel)
7. 在人气道、肠道和大脑等器官模型中评估氢溴酸常山酮的广谱宿主靶向抗病毒疗效。
(Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models)
作者：Inés García-Rodríguez, Carlemi Calitz* (Emma Children's Hospital, Department of Pediatric Infectious Diseases, Amsterdam UMC, Location Academic Medical Center, Amsterdam Institute for Infection and Immunity, Amsterdam Institute for Reproduction and Development, University of Amsterdam, the Netherlands)
8. 经鼻给药的超保守siRNA可预防性抑制肺部和鼻腔的SARS-CoV-2感染。
(An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity)
作者：Adi Idris* (Menzies Health Institute Queensland, Griffith University, Australia)
9. 口服USC-093是酪氨酸酰胺(S)-HPMPA前体药物USC-087的新型高丝氨酸酰胺类似物，其肾毒性降低的同时对叙利亚仓鼠的人腺病毒感染保持抗病毒疗效
(Oral USC-093, a novel homoserinamide analogue of the tyrosinamide (S)-HPMPA prodrug USC-087 has decreased nephrotoxicity while maintaining antiviral efficacy against human adenovirus infection of Syrian hamsters)
作者：Ann E. Tollefson, Charles E. McKenna* (Saint Louis University School of Medicine, USA; University of Southern California, USA)
10. 高通量药物筛选确定可降低JCPyV感染的钙和钙调蛋白抑制剂
(High-throughput drug screen identifies calcium and calmodulin inhibitors that reduce JCPyV infection)
作者：Avery C.S. Bond, Melissa S. Maginnis* (Department of Molecular and Biomedical Sciences, The University of Maine, USA)
11. 蛋白酶抑制剂耐药SARS-CoV-2毒株的产生和评估
(Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains)
作者：Hawa Sophia Bouzidi, Jean-Sélim Driouich, Raphaëlle Klitting,  Franck Touret* (Unité des Virus Émergents, UVE: Aix Marseille Univ, France)
12. 通过人工智能发现新的抗病毒药物：体外和体内结果
(Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results)
作者：Roza Izmailyan, Hovakim Zakaryan* (Laboratory of Antiviral Drug Discovery, Institute of Molecular Biology of NAS, USA)
13. cGAS-STING的激活通过干扰素依赖的信号传导抑制柯萨奇病毒的复制
(Activation of cGAS-STING suppresses coxsackievirus replication via interferon-dependent signaling)
作者：Yasir Mohamud, Honglin Luo* (Centre for Heart Lung Innovation, St Paul's Hospital, Canada)
14. HAND2抑制法匹拉韦治疗博尔纳病病毒感染的疗效
(HAND2 suppresses favipiravir efficacy in treatment of Borna disease virus infection)
作者：Da Teng, Tomoyuki Honda* (Division of Virology, Department of Microbiology and Immunology, Osaka University Graduate School of Medicine, Japan)
15. 鼻病毒通过远离结合囊袋的突变逃逸吡唑并[3,4-d]嘧啶衣壳结合抑制剂OBR-5-340的分子机制：具有制动抗性的衍生物
(Molecular mechanism of rhinovirus escape from the Pyrazolo[3,4-d]pyrimidine capsid-binding inhibitor OBR-5-340 via mutations distant from the binding pocket: Derivatives that brake resistance)
作者：Martina Richter, Vadim Makarov* (Jena University Hospital, Department Medical Microbiology, Section Experimental Virology, Germany; Federal Research Centre “Fundamentals of Biotechnology” of the Russian Academy of Sciences (Research Centre of Biotechnology RAS), Russia)
16. 抗人呼吸道合胞病毒抗体发展的分子角度
(A molecular perspective for the development of antibodies against the human respiratory syncytial virus)
作者：Ricardo A. Loaiza, Alexis M. Kalergis* (Millennium Institute on Immunology and Immunotherapy, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Chile)
17. 用于HIV-1治愈策略的下一代bNAbs
(Next-generation bNAbs for HIV-1 cure strategies)
作者：A.I. Schriek* (Amsterdam UMC Location University of Amsterdam, Department of Medical Microbiology, the Netherlands)
18. 单域抗体控制流感的前景与挑战
(Promises and challenges of single-domain antibodies to control influenza)
作者：Arne Matthys, Xavier Saelens* (VIB Center for Medical Biotechnology, Belgium)

八、英国药理学杂志 (2024年第181卷第3-4期)

（一）February 2024 - Volume 181 - Issue 3 (2024年2月第181卷第3期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2024/181/3

Invited Review（特约综述）
1. 驯服顽固性高血压：新型药物疗法和肾去神经术的前景
(Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation)
作者：Omar Azzam, Markus P. Schlaich* (Dobney Hypertension Centre, Medical School—Royal Perth Hospital Unit, Royal Perth Hospital Medical Research Foundation, The University of Western Australia, Australia)

Mini Review（简短综述）
1. 药物发现：在计算机模拟中，干数据可以绕过生物湿数据吗？
(Drug discovery: In silico dry data can bypass biological wet data?)
作者：Massimiliano Tognolini* (Department of Food and Drug, University of Parma, Italy)

Rapid Communication（快速通讯）
1. 基于RNA的SARS-CoV-2疫苗的心脏副作用：mRNA-1273和BNT162b2对心室肌细胞功能和结构的隐性心脏毒性作用
(Cardiac side effects of RNA-based SARS-CoV-2 vaccines: Hidden cardiotoxic effects of mRNA-1273 and BNT162b2 on ventricular myocyte function and structure)
作者：Rolf Schreckenberg* (Institute of Physiology, Faculty of Medicine, Justus-Liebig University, Germany)

Bioinformatic Tool（生物信息学工具）
1. 转录组水平的非小细胞肺癌生存相关生物标志物和治疗靶点的发现
(Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer)
作者：Balázs Győrffy* (Department of Bioinformatics, Semmelweis University, Hungary)

Research Articles（研究文章）
1. 定义和揭示药理学的核心概念：一项全球倡议
(Defining and unpacking the core concepts of pharmacology: A global initiative)
作者：Clare Guilding* (School of Medicine, Faculty of Medical Sciences, Newcastle University, UK)
2. 抑制p38MAPK信号通路可通过改善精子发生减轻放射性睾丸损伤
(Inhibition of p38MAPK signalling pathway alleviates radiation-induced testicular damage through improving spermatogenesis)
作者：Juan Yang, Lijian Shao* (School of Public Health, Jiangxi Provincial Key Laboratory of Preventive Medicine, Nanchang University, China)
3. 多巴胺通过胆碱能依赖和非依赖途径调节结肠胶质细胞源性神经营养因子的分泌
(Dopamine regulates colonic glial cell-derived neurotrophic factor secretion through cholinergic dependent and independent pathways)
作者：Xiao-Li Zhang*, Jin-Xia Zhu* (Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, China)
4. 类风湿关节炎中中性粒细胞胞外诱捕网通过增强RANKL诱导的破骨细胞生成介导骨侵蚀
(Neutrophil extracellular traps mediate bone erosion in rheumatoid arthritis by enhancing RANKL-induced osteoclastogenesis)
作者：Ayda Henriques Schneider, Fernando Queiróz Cunha* (Center of Research in Inflammatory Diseases, Ribeirao Preto Medical School, University of Sao Paulo, Brazil)
5. 甘草代谢物18β-甘草次酸激活G蛋白门控的内向整流钾离子通道
(Licorice metabolite 18β-glycyrrhetinic acid activates G protein-gated inwardly rectifying K+ channels)
作者：I-Shan Chen* (Department of Pharmacology, Faculty of Medicine, Wakayama Medical University, Japan)
6. 在一体化离体肾移植和纤维增生模型中，使用机械灌注的galunisertib靶向递送可减少纤维生成
(Targeted delivery of galunisertib using machine perfusion reduces fibrogenesis in an integrated ex vivo renal transplant and fibrogenesis model)
作者：L. Leonie van Leeuwen* (Department of Surgery, University Medical Center Groningen, University of Groningen, The Netherlands)
7. PACAP-38相关的颅副交感神经投射调节：严重原发性头痛的一种新机制和治疗靶点
(PACAP-38 related modulation of the cranial parasympathetic projection: A novel mechanism and therapeutic target in severe primary headache)
作者：Simon Akerman* (Department of Neural and Pain Sciences, University of Maryland Baltimore, USA)

Short Report（短报告）
1. 药物抑制整合应激反应加速肌萎缩侧索硬化小鼠模型的疾病进展
(Pharmacological inhibition of the integrated stress response accelerates disease progression in an amyotrophic lateral sclerosis mouse model)
作者：Elías Marlin, Montserrat Arrasate* (Gene Therapy and Regulation of Gene Expression Program, Center for Applied Medical Research (CIMA), University of Navarra, Spain)

（二）February 2024 - Volume 181 - Issue 4 (2024年2月第181卷第4期)
https://bpspubs.onlinelibrary.wiley.com/toc/14765381/2024/181/4

Platelet Purinergic Receptor And Non-Thrombotic Disease - Editorial（血小板嘌呤能受体与非血栓性疾病-社论）
1. 血小板嘌呤能受体与非血栓性疾病
(Platelet purinergic receptors and non-thrombotic diseases)
作者：Simon C. Pitchford* (Pulmonary Pharmacology Unit, Institute of Pharmaceutical Science, King's College London, UK)

Platelet Purinergic Receptor And Non-Thrombotic Disease - Themed Issue Review（血小板嘌呤能受体与非血栓性疾病-主题刊综述）
1. 血小板P2Y₁₂受体在炎症中的作用
(The role of platelet P2Y₁₂ receptors in inflammation)
作者：William A. E. Parker* (Cardiovascular Research Unit, Division of Clinical Medicine, University of Sheffield, UK)
2. 血小板P2Y₁₂信号通路在脓毒症免疫应答失调中的作用
(Platelet P2Y₁₂ signalling pathway in the dysregulated immune response during sepsis)
作者：Emmanuel Boadi Amoafo, Elisabetta Liverani* (Department of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, USA)
3. 炎症期间通过腺苷受体调节血小板功能的可能性
(Potential for modulation of platelet function via adenosine receptors during inflammation)
作者：Magdalena Boncler, Marcin Rozalski* (Department of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Poland)

Platelet Purinergic Receptor And Non-Thrombotic Disease - Themed Issue Article（血小板嘌呤能受体与非血栓性疾病-主题刊文章）
1. 不同内源性核苷酸对血小板P2Y₁受体的刺激通过偏倚信号传导导致功能选择性
(Stimulation of platelet P2Y₁ receptors by different endogenous nucleotides leads to functional selectivity via biased signalling)
作者：Kate L. Arkless, Simon C. Pitchford* (Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, UK)

Platelet Purinergic Receptor And Non-Thrombotic Disease - Themed Issue Review（血小板嘌呤能受体与非血栓性疾病-主题刊综述）
1. 探索血小板P2Y₁信号传导的偏倚：宿主防御对抗止血
(Exploring bias in platelet P2Y₁ signalling: Host defence versus haemostasis)
作者：Dingxin Pan, Simon C. Pitchford* (Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, UK)

九、临床药代动力学 (2024年第63卷第2期)

Februauy 2024 -Volume 63 - Issue 2 (2024年2月第63卷第2期)
https://link.springer.com/journal/40262/volumes-and-issues/63-2

Commentary（评论）
1. Logit、Box-Cox和其他非对数正态参数的变异报告系数
(Reporting Coefficient of Variation for Logit, Box-Cox and Other Non-log-normal Parameters)
作者：John P. Prybylski* (Pharmacometrics, Worldwide Research and Development Medicine, Pfizer, USA)

Review Article（综述文章）
1. 治疗中度至重度银屑病的临床药代动力学和药效学考虑
(Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis)
作者：Jonathan Greenzaid* (Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, USA)
2. 应用药代动力学和药效学数据开发用于晚期乳腺癌患者的CDK4/6抑制剂瑞博西利
(Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer)
作者：Yan Ji* (Novartis Pharmaceuticals Corporation, USA)
3. Lorlatinib对晚期非小细胞肺癌患者CYP2B6、CYP2C9、UGT和p -糖蛋白底物的影响评估
(Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer)
作者：Joseph Chen, Jacqueline Gerhart* (Pfizer, USA)

Original Research Article（原创研究文章）
1. 在癌症血液病患者中实现基于模型的万古霉素的知情精确给药：第一步
(Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step)
作者：Jessica Le Blanc, Amélie Marsot* (Faculté de Pharmacie, Université de Montréal, Canada)
2. 模型引导的精准用药用于减少儿童患者长春新碱诱导的周围神经病变：药代动力学和药效学模型和模拟分析
(Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis)
作者：Maddalena Centanni, Lena E. Friberg* (Department of Pharmacy, Uppsala University, Sweden)
3. 体外循环期间影响普通肝素药代动力学和药效学的因素
(Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass)
作者：Audrick Gibert* (INSERM, U1059, Dysfonction Vasculaire et Hémostase, France)
4. HSK7653片在中国肾功能正常或受损人群中的药代动力学、药效学和安全性
(Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function)
作者：Dan Shi, Meixia Wang* (Department of Nephrology, Beijing Jishuitan Hospital, Capital Medical University, China; Clinical Trial Institution Management Office, Beijing Jishuitan Hospital, Capital Medical University, China)
5. 单次静脉输注后，[14C]来那帕韦（一种新型的HIV-1衣壳功能选择性抑制剂）在健康参与者中的药代动力学、处置和生物转化
(Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion)
作者：Elijah Weber, Renu Singh* (Gilead Sciences, Inc., USA)
6. Cotadutide的群体药代动力学模型：一种胰高血糖素样肽和胰高血糖素受体的双重激动肽，用于患2型糖尿病、慢性肾脏病、肥胖和非酒精性脂肪性肝炎的参与者
(Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis)
作者：Hongtao Yu* (Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, USA)